We spoke with Mrinal M. Gounder, MD, about next-generation sequencing for sarcoma, and how it can be used to inform treatment decisions and prognosis.
An experimental compound known as G100 may be a potentially viable agent for local control of metastatic soft tissue sarcomas.
Sarcomas are a heterogeneous and motley collection of cancers, which struggle with an identity crisis on many levels. The trials often lump vastly different subgroups, and are often unable to collect sufficient numbers of any one disease subtype to complete a unique cohort.
Advanced imaging techniques could allow clinicians the ability to determine as early as 9 days into sarcoma treatment whether the therapy will be effective in a given patient, according to a new University of Michigan study.
T cells that express a HER2-specific chimeric antigen receptor showed promise as a treatment for HER-2 positive sarcoma in a small phase I/II trial.
The concept of individualized or personalized medicine in oncology has evolved from the use of imatinib (Gleevec) to target the breakpoint cluster region-Abelson protein (BCR-ABL) in chronic myelogenous leukemia, to next generation sequencing panels able to provide more complete genetic analysis of a given tumor or malignant cell.